BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discov Today 2017;22:1148-64. [PMID: 28400153 DOI: 10.1016/j.drudis.2017.03.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang L. CTRP4: a new member of the adipocytokine family. Cell Mol Immunol 2017;14:868-70. [PMID: 29026217 DOI: 10.1038/cmi.2017.83] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Kyrochristos ID, Ziogas DE, Goussia A, Glantzounis GK, Roukos DH. Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. Cancers (Basel) 2019;11:E1809. [PMID: 31752125 DOI: 10.3390/cancers11111809] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
3 Ziogas DE, Kyrochristos ID, Roukos DH. Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. Drug Discovery Today 2018;23:1848-72. [DOI: 10.1016/j.drudis.2018.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
4 Kyrochristos ID, Ziogas DE, Roukos DH. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma. Future Oncol 2017;13:1665-8. [PMID: 28613123 DOI: 10.2217/fon-2017-0237] [Reference Citation Analysis]
5 Ma X, Kang X, He L, Zhou J, Zhou J, Sturm MB, Beer DG, Kuick R, Nancarrow DJ, Appelman HD, Pang Z, Li W, Zhang C, Zhang W, Zhang Y, Wang TD, Li M. Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application. Mol Pharm 2019;16:2199-213. [PMID: 30974945 DOI: 10.1021/acs.molpharmaceut.9b00185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Antoniou P, Ziogas DE, Mitsis M, Roukos DH. Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. Future Oncol 2019;15:1805-10. [PMID: 31170806 DOI: 10.2217/fon-2019-0132] [Reference Citation Analysis]
7 Ziogas DE, Kyrochristos ID, Roukos DH. Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology. Expert Review of Medical Devices 2017;15:1-3. [DOI: 10.1080/17434440.2017.1419059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Med Res Rev 2019;39:1205-27. [PMID: 30417574 DOI: 10.1002/med.21549] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
9 Pappas-Gogos G, Baltagiannis EG, Kyrochristos ID, Ziogas DE, Goussia A, Mitsis M, Roukos DH. Predictive and patient-monitoring biomarkers: precision in the management of colorectal cancer. Biomark Med 2020;14:335-9. [PMID: 32250157 DOI: 10.2217/bmm-2020-0025] [Reference Citation Analysis]
10 Ziogas DE, Kyrochristos ID, Lykoudis EG, Roukos DH. Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. Biomarkers in Medicine 2018;12:1197-201. [DOI: 10.2217/bmm-2018-0269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Baltagiannis EG, Kyrochristos ID, Ziogas DE, Goussia A, Mitsis M, Roukos DH. From personalized to precision cancer medicine. Per Med 2020;17:245-50. [PMID: 32589113 DOI: 10.2217/pme-2020-0056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Chen Z, Zhang C, Zhang M, Li B, Niu Y, Chen L, Yang J, Lu S, Gao J, Shen L. Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer.Cell Death Dis. 2019;10:697. [PMID: 31541076 DOI: 10.1038/s41419-019-1907-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kyrochristos ID, Ziogas DE, Glantzounis GK, Roukos DH. Prediction of pancreatic cancer risk and therapeutic response with next-generation sequencing. Biomark Med 2018;12:5-8. [PMID: 29235881 DOI: 10.2217/bmm-2017-0315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Kyrochristos ID, Ziogas DE, Roukos DH. Precision in personalized prediction-based medicine. Per Med 2018;15:467-70. [PMID: 30387685 DOI: 10.2217/pme-2018-0079] [Reference Citation Analysis]
15 Kyrochristos ID, Baltagiannis EG, Mitsis M, Roukos DH. Precision in cancer pharmacogenomics. Pharmacogenomics 2020;21:311-6. [PMID: 32242500 DOI: 10.2217/pgs-2020-0011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kyrochristos ID, Roukos DH. Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treat Rev 2019;80:101894. [PMID: 31518831 DOI: 10.1016/j.ctrv.2019.101894] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
17 Antoniou P, Ziogas DE, Vlachioti A, Lykoudis EG, Mitsis M, Roukos DH. Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer. Per Med 2019;16:361-4. [PMID: 31507233 DOI: 10.2217/pme-2019-0036] [Reference Citation Analysis]
18 Kyrochristos ID, Peristeri DV, Ziogas DE, Lykoudis EG, Roukos DH. Precise predictive and therapeutic strategy for breast cancer. Future Oncol 2018;14:1777-80. [PMID: 29846090 DOI: 10.2217/fon-2018-0277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Kyrochristos ID, Ziogas DE, Roukos DH. Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. Drug Discov Today 2019;24:1281-94. [PMID: 31009757 DOI: 10.1016/j.drudis.2019.04.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
20 Kyrochristos ID, Ziogas DE, Antoniou P, Mitsis M, Lykoudis EG, Roukos DH. Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. Pharmacogenomics 2018;19:1303-10. [PMID: 30348059 DOI: 10.2217/pgs-2018-0141] [Reference Citation Analysis]
21 Kyrochristos ID, Ziogas DE, Lykoudis EG, Roukos DH. Breast cancer genome analysis in time and space: biomarker development strategy. Biomark Med 2018;12:547-50. [PMID: 29873520 DOI: 10.2217/bmm-2018-0109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hampel H, Goetzl EJ, Kapogiannis D, Lista S, Vergallo A. Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. Front Pharmacol 2019;10:310. [PMID: 30984002 DOI: 10.3389/fphar.2019.00310] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
23 Kyrochristos ID, Ziogas DE, Glantzounis GK, Roukos DH. Molecular landscape of pancreatic cancer: challenges and clinical implications. Future Oncol 2017;13:2741-4. [PMID: 29182377 DOI: 10.2217/fon-2017-0335] [Reference Citation Analysis]
24 Kyrochristos ID, Glantzounis GK, Goussia A, Eliades A, Achilleos A, Tsangaras K, Hadjidemetriou I, Elpidorou M, Ioannides M, Koumbaris G, Mitsis M, Patsalis PC, Roukos D. Proof-of-Concept Pilot Study on Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis. Front Oncol 2022;12:855463. [DOI: 10.3389/fonc.2022.855463] [Reference Citation Analysis]
25 Baltagiannis EG, Ziogas DE, Cho WC, Mitsis M, Roukos DH. Tumor heterogeneity-driven individualized therapy. Future Oncol 2021;17:235-40. [PMID: 33305621 DOI: 10.2217/fon-2020-0915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S; Alzheimer Precision Medicine Initiative. Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology 2021;185:108081. [PMID: 32407924 DOI: 10.1016/j.neuropharm.2020.108081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Dai Z, Gu XY, Xiang SY, Gong DD, Man CF, Fan Y. Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells. Biomark Res 2020;8:60. [PMID: 33292625 DOI: 10.1186/s40364-020-00240-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]